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Isotretinoin, synthetic vitamin A for severe acne, is a known human teratogen that
can cause multiple malformations, including birth defects and intrauterine fetal
death. The drug was contraindicated in women who are or may become pregnant
during therapy or in the following month, especially within one month. We present a
case of ear malformation in a newborn whose mother had taken isotretinoin for 2
years until one month prior to the time when she became pregnant.  
A one-day-old term male neonate was brought to NICU for evaluation of mal-
formation of ear. His mother, a 24-year-old nulliparous woman, had taken 10 mg
of Ro-accutane® (isotretinoin) for approximately 2 years due to severe acne. She
has used an intrauterine device for contraception during the treatment of Ro-
accutane®. She was 10 weeks pregnant when she visited the hospital. She had
regular 30 day menstruation cycle, and discontinued the use of isotretinoin about
13 weeks ago, meaning that after 5 weeks of discontinuation, fertilization was
achieved. She received regular antenatal care during the 1st trimester of pregnancy
and there were no noticeable events. Ultrasonographic exam was done only at 10
weeks and 20 weeks of pregnancy, and no definite malformation was confirmed.
The baby’s birth was uneventful and weighed 3.8 kg at birth. On examination, the
baby was conscious and lively. His right ear was deformed and microtic with a
visible opening of ear canal, however there was only a skin tag-like remnant of
lower part of ear lobe with no opening on the left side (Fig. 1). The other features
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of HEENT, cardiovascular and CNS systems were within
normal limits. Tympanic bone computer tomography showed
atresia of bilateral external auditory canal and dilatation of
both vestibules (Fig. 2). Brain MRI showed no discernible
abnormalities. 
Accutane®, known by the generic name “isotretinoin,” is a
prescription oral medication first approved in 1982 by the
Food and Drug Administration (FDA) to treat severe, recal-
citrant nodular acne. The concern about human teratogenicity
proved well founded, because it was soon demonstrated that
approximately 25 to 30 percent of exposed fetuses had birth
defects - the so-called accutane embryopathy, consisting of
craniofacial, heart, and central nervous system defects.1
Malformations frequently observed include microtia/anotia,
micrognathia, cleft palate, defects of the auditory canals,
facial dysmorphy, heart and aortic arch defects, thymic
hypoplasia, microcephaly, hydrocephaly, retina or optic
nerve abnormalities, and functional impairment. This issue
was taken up and reviewed by an advisory committee to the
US FDA in 1988. Following the guidance by the FDA, the
manufacturer began a pregnancy-prevention program (PPP)
in the same year and developed a new risk management
program, the System to Manage Accutane-Related Terato-
genicity (SMART), in 2002.2,3 Although the teratogenicity
of this drug is well known and risk-management programs
had been implemented, preventable fetal exposures have
continued, largely as a result of the lack of sufficient controls
within the programs themselves.4 The manufacturers of
isotretinoin implemented a new risk-management program,
iPLEDGE, in March 2006.5 iPLEDGE is a comprehensive
distribution system that includes mandatory registration of
patients, healthcare providers, pharmacists, and wholesalers.
It allows real-time linkage of pregnancy-test results for
verification prior to the dispensing of isotretinoin. 
There has been numerous reviews about retinoid-induced
ear malformation. In in vivo and in vitro studies, isotretinoin
interferes directly with the development of cranial neural
crest cells.6 Earlier exposure in utero produces microtia, auri-
cular duplication, anotia, temporal bone abnormalities and
ossicular malformation. However, an exposure at later
developmental stage results in facial tags with less severely
affected ears. 
The prevelance of microtia has been reported to vary from
0.83 to 17.4/10,000. Microtia has been associated with nume-
rous risk factors such as prenatal exposure to drugs, paternal
age, maternal age, high parity, first parity, maternal diabetes,
male gender, urban area, altitude, and low birth weight.7 In
our case, no typical drug exposure except isotretinoin was
found, and no specific history was revealed. 
Despite prominent warnings, reports of pregnancies in
exposed women continues to accumulate, and malformed
infants have been reported. The Slone Survey was an inde-
pendent follow-up survey of women of childbearing age
who were prescribed isotretinoin between January 1989
through June 2000 in which 1,019 exposed pregnancies
were identified.3 Of these, 117 live births were recorded and
887 terminations, including 681 elective terminations, 177
spontaneous abortions, and 29 ectopic pregnancies. Of the
63 live births for which records were examined, 13% showed
major malformations and 30% showed some degree of
malformation. 
Malformations may occur even with short periods of use
only. Therefore, no systemic dose of isotretinoin is consi-
dered safe during pregnancy.7 Hersh et al.8 reported that 10%
of live birth records examined showed malformations of
pregnancies occurring within 30 days after isotretinoin
discontinuation. However, women who conceive one cycle
after discontinuing isotretinoin are advised that their terato-
genic risk is not higher than baseline.9
The elimination half-life of isotretinoin has been reported
to be 10-20 hours, and its metabolites, 4-oxo-isotretinoin,
17 to 50 hours. The pharmacokinetics of isotretinoin (0.47
to 1.7 mg/kg/day) were studied in a small number of child-
bearing age women, and the results suggested that the half-
life may be more variable and/or longer than previously
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Fig. 1. Microtia on right side, and anotia on leftside.
Fig. 2. Absence of left ear canal and small right ear canal, but bony atresia and
fusion of osscicle and hemorrhage around the ossicle.
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reported, thus affecting the length of time for safe concep-
tion after drug discontinuation.10 In one patient who exhibited
an abnormally long elimination half-life of the drug , the t1/2
values for isotretinoin and its 4-oxo metabolite were 12.9
hours and 60.75 hours, respectively. The present results
confirmed a prolonged t1/2 in a patient, which might have
been due to hepatic recirculation. Even in the worst-case
scenario (t1/2 of approximately one week), five times of t1/2 s,
which are needed to allow levels to return to baseline would
be a 35-day period before safe conception.10 According to
iPLEGE program, the patient is advised to have a negative
pregnancy test before isotretinoin use, every month during
treatment, at the end of treatment and 1 month after stop-
ping treatment. 
Herein, we found a case of ear malformation occurring
after 1 month of isotretinoin discontinuation. We, therefore,
suggest that a new guideline recommending a longer duration
of isotretinoin discontinuation before conception and further
studies of pharmacokinetics isotreinoin are needed.  
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